The HardRealities of Building in Healthcare
Founders who think they can “move fast and break things” quickly discover that the healthcare arena operates by a different rulebook. Development timelines stretch far beyond typical tech cycles, the stakes are exceptionally high, and success hinges on mastering a system that prizes rigorous evidence over rapid iteration. This is the world Robhy Bustami, co‑founder and CEO of BioticsAI, has been navigating since day one.
Meet Robhy Bustami and BioticsAI
Bustami leads a small but ambitious team that is building an AI copilot for ultrasound designed to detect fetal abnormalities—an area where misdiagnosis rates remain unacceptably high. In a recent episode of Build Mode, he sat down with Isabelle Johannessen to explain how his company has steered through a heavily regulated environment while keeping its team motivated and its product moving forward.
From Scrappy Prototype to FDA Clearance
BioticsAI launched with a lean, scrappy approach. The team created a functional version of the ultrasound AI for under $100,000, a figure that is almost unheard of in the medical device sector. That early prototype earned them a spot in the prestigious TechCrunch Startup Battlefield 2023 competition, delivering crucial visibility and credibility that helped attract investors and partners.
In January of this year, BioticsAI secured FDA approval, unlocking the ability to deploy its technology in hospitals and accelerate commercial growth. The clearance was not a lucky accident; it was the result of a strategy that embedded regulatory considerations from the outset.
Strategic Integration of Regulation and Product Development
Rather than building a product first and tackling compliance later, BioticsAI wove clinical validation, regulatory strategy, and product design into a single, continuous process. This meant:
- Collaborating closely with clinicians to define the clinical use cases and data requirements.
- Collecting large‑scale, diverse datasets that reflected real‑world ultrasound imaging conditions.
- Running structured clinical studies that generated the evidence needed for FDA submission.
According to Bustami, early engagement with the FDA—through pre‑submission meetings—allowed the team to align on study design, endpoints, and the evidentiary standards the agency would expect. While the FDA pathway can feel like a black box, proactive dialogue turned it into a predictable roadmap rather than a gamble.
Motivating a Team Through Long Timelines
Securing FDA clearance is only the first major milestone; the journey from prototype to hospital deployment can span years. For many investors, the pivotal question is: “What if the FDA says no?” Internally, those extended timelines pose a different challenge: maintaining momentum when the biggest win feels distant.
BioticsAI addressed this by cultivating a culture of alignment across engineers, clinicians, and researchers. The company ensures that every team member can see tangible progress—whether it’s a successful pilot study, a new healthcare partnership, or a technical breakthrough—so that motivation stays high even when the ultimate goal remains years away. As Bustami explains, “Making sure everyone is completely aligned, even if it’s outside of their technical scope, and constantly seeing wins on the R&D side” is key to sustaining energy.
Deployment and Future Expansion
With FDA clearance now in hand, BioticsAI is moving into the deployment phase. The company has begun rolling out its AI copilot in selected hospitals, focusing initially on obstetrics. Plans are already underway to broaden the technology’s scope to other areas of reproductive health, creating a versatile platform that can address a range of prenatal diagnostic needs.
This expansion represents more than a product launch; it signals a shift from experimental validation to real‑world impact. By integrating AI into the ultrasound workflow, BioticsAI aims to reduce misdiagnosis rates, streamline decision‑making for clinicians, and ultimately improve outcomes for mothers and babies.
Why the Long Game Matters for Health Tech Founders
Building in healthcare demands patience, discipline, and a willingness to operate in uncertainty. The reward for founders who embrace this long game is twofold: a sustainable, impact‑driven company and the chance to reshape how care is delivered. For BioticsAI, the FDA clearance is not just a regulatory checkbox—it is a validation of a meticulous, evidence‑first approach that can serve as a template for other health tech innovators.
Conclusion: Patience, Partnership, and Impact
Robhy Bustami’s journey with BioticsAI illustrates that success in the healthcare sector is earned through rigorous preparation, strategic collaboration, and steadfast team alignment. By integrating FDA considerations early, investing in robust clinical validation, and fostering a culture that celebrates incremental wins, the company has turned a modest $100,000 prototype into a cleared medical device poised for hospital deployment. As the startup moves beyond obstetrics into broader reproductive health applications, it exemplifies how thoughtful, patient‑centered development
Your Opinion is valid .